Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Dapagliflozin Review To Focus On Hepatic Effects, Cancer Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency will ask its Endocrinologic and Metabolic Drugs Advisory Committee to weigh these "unexpected" safety findings despite a clean cardiovascular profile for Bristol-Myers Squibb/AstraZeneca's first-in-class diabetes drug.
Advertisement

Related Content

Stringent Hepatic Monitoring Urged For Diabetes Drug Clinical Trials
Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns
Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns
Stringent Hepatic Monitoring Urged For Diabetes Drug Clinical Trials
Dapagliflozin Cancer Signal Weighs Heavily In FDA Panel's Negative Vote
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
New Data Help Size Up Novel Class Of SGLT-2 Inhibitors In Diabetes
New Data Help Size Up Novel Class Of SGLT-2 Inhibitors In Diabetes
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
FDA Diabetes Guidance Encourages Enrollment Of Sicker Patients

Topics

Advertisement
UsernamePublicRestriction

Register

PS072517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel